Skip to main content
LBRX
NASDAQ Life Sciences

LB Pharmaceuticals Posts $59.1M Q3 Loss; $403.8M Cash Funds Operations Past Q2 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$38.09
Mkt Cap
$1.229B
52W Low
$14.317
52W High
$50.16
52W Position info
166% above low
Off High info
24% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

LBRX has more than doubled off its 52-week low of $14.317.

Summary

LB Pharmaceuticals reported a $59.1M third-quarter loss driven by Phase 3 R&D spending, but ended September with $403.8M in cash and guided to runway beyond Q2 2029 — past the NOVA-2 topline readout expected in the first half of 2027.


Key Events · Earnings and Guidance · LBRX

  • Q3 Loss Widens on Trial Costs

    Net loss was $59.1M ($1.79 per share) for the three months ended September 30, 2026, versus $3.6M a year earlier; nine-month net loss reached $129.7M.

  • R&D Spend Jumps to $51.5M

    Research and development expense rose to $51.5M from $2.4M in Q3 2025, driven by the Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression.

  • Cash Runway Past Q2 2029

    Cash, cash equivalents and short-term investments totaled $403.8M at September 30, 2026, which management expects to fund operations beyond the second quarter of 2029.

  • NOVA-2 Topline in 1H 2027

    Enrollment in the pivotal Phase 3 NOVA-2 trial continues, with topline data expected in the first half of 2027 and a pre-NDA FDA meeting planned for the second half of 2027.


Analysis · LBRX · Life Sciences

The quarterly loss looks large in absolute terms, but it is largely mechanical. R&D jumped to $51.5M from $2.4M a year ago as the Phase 3 NOVA-2 schizophrenia trial and the Phase 2 bipolar depression trial now run at full cost, and the share count roughly quintupled year over year after the July $150M private placement. What actually matters is the balance sheet: $403.8M of cash and short-term investments, with management guiding runway beyond Q2 2029. That covers the NOVA-2 topline readout expected in the first half of 2027 and the pre-NDA meeting planned for the second half of 2027 without another raise. The derivative fair-value line was a $342K non-cash charge, not a cash outflow. With financing risk pushed out several years, the stock's next real driver is the NOVA-2 data, not this P&L.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LBRX was trading at $38.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.32 to $50.16. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LBRX - Latest Insights

LBRX
Nov 05, 2026, 8:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $38.09
Real-time Price: $41.00 info
Change: +$2.91 (+8%) info
Market Cap: $1.296B info
LBRX
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $38.09
Real-time Price: $41.00 info
Change: +$2.91 (+8%) info
Market Cap: $1.296B info
LBRX
Oct 01, 2026, 4:05 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $37.28
Real-time Price: $41.00 info
Change: +$3.72 (+10%) info
Market Cap: $1.296B info
LBRX
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $46.76
Real-time Price: $41.00 info
Change: -$5.76 (-12%) info
Market Cap: $1.296B info
LBRX
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $46.76
Real-time Price: $41.00 info
Change: -$5.76 (-12%) info
Market Cap: $1.296B info